iBio, Inc. (IBIO) — SEC Filings

Latest SEC filings for iBio, Inc. (IBIO), explained in plain English.

Sentiment Overview: 1 bullish, 3 bearish, 41 neutral, 3 mixed

Recent Filings (48)

• iBio, Inc. Submits Matters to Security Holders — 8-K · 2025-11-21T00:00:00.000Z [neutral] Risk: medium
  On November 20, 2025, iBio, Inc. filed an 8-K report to announce that it submitted matters to a vote of its security holders. The filing does not specify the na
• iBio's Q1 Loss Widens to $5.7M, Cash Reserves Jump Post-$50M Offering — 10-Q/A · 2025-11-17T00:00:00.000Z [mixed] Risk: medium
  iBio, Inc. (IBIO) reported a net loss of $5.72 million for the three months ended September 30, 2025, an increase from a net loss of $3.99 million in the same p
• iBio's R&D Surge Drives Wider Loss, Bolstered by $50M Capital Raise — 10-Q · 2025-11-12T00:00:00.000Z [mixed] Risk: high
  iBio, Inc. reported a net loss of $5.72 million for the three months ended September 30, 2025, an increase from a net loss of $3.99 million in the same period o
• iBio, Inc. Files 8-K Report — 8-K · 2025-11-04T00:00:00.000Z [neutral] Risk: low
  On November 4, 2025, iBio, Inc. filed an 8-K report. The filing indicates that the company is located at 11750 Sorrento Valley Road, Suite 200, San Diego, Calif
• iBio, Inc. Files 8-K Report — 8-K · 2025-10-30T00:00:00.000Z [neutral] Risk: low
  On October 30, 2025, iBio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation F
• iBio Sets 2025 Annual Meeting: Director Elections, Auditor Ratification on Docket — DEF 14A · 2025-10-06T00:00:00.000Z [neutral] Risk: low
  iBio, Inc. (IBIO) is holding its 2025 Annual Meeting of Stockholders on November 20, 2025, in San Diego, California. Stockholders will vote on four key proposal
• iBio Raises $46.5M, Advances Obesity Pipeline with AI-Driven Antibodies — 10-K · 2025-09-05T00:00:00.000Z [mixed] Risk: high
  iBio, Inc. (IBIO) is a preclinical stage biotechnology company focused on developing precision antibodies for cardiometabolic and obesity treatments, leveraging
• iBio, Inc. Files 8-K: Material Agreement & Disclosures — 8-K · 2025-08-21T00:00:00.000Z [neutral] Risk: medium
  On August 19, 2025, iBio, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also made
• iBio, Inc. Files 8-K with Financial Updates — 8-K · 2025-08-18T00:00:00.000Z [neutral] Risk: medium
  On August 18, 2025, iBio, Inc. filed an 8-K report detailing significant events. The filing includes information on the company's results of operations and fina
• iBio Faces NYSE American Delisting Threat — 8-K · 2025-08-01T00:00:00.000Z [bearish] Risk: high
  On July 29, 2025, iBio, Inc. filed an 8-K report indicating a potential delisting from the NYSE American. The company received a notice from the exchange regard
• iBio, Inc. Files 8-K with Regulatory Disclosures — 8-K · 2025-06-24T00:00:00.000Z [neutral] Risk: medium
  On June 24, 2025, iBio, Inc. filed an 8-K report detailing several events. The company announced a Regulation FD Disclosure, indicating a public disclosure of m
• iBio, Inc. Files 8-K Report — 8-K · 2025-06-18T00:00:00.000Z [neutral] Risk: low
  On June 17, 2025, iBio, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as iBioPharma, Inc., is incorporat
• iBio, Inc. Q3 2025: Revenue $0.22M, Net Loss $2.25M — 10-Q · 2025-05-02T00:00:00.000Z [bearish] Risk: medium
  iBio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $9.86 million and total liabilities of $3.71 million. For t
• iBio, Inc. Files 8-K: Material Agreement, Exhibits — 8-K · 2025-04-22T00:00:00.000Z [neutral] Risk: medium
  On April 21, 2025, iBio, Inc. entered into a Material Definitive Agreement. The filing also includes a Regulation FD Disclosure and Financial Statements and Exh
• iBio, Inc. Files 8-K Report — 8-K · 2025-04-08T00:00:00.000Z [neutral] Risk: low
  On April 8, 2025, iBio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD d
• iBio, Inc. Files 8-K Report — 8-K · 2025-04-07T00:00:00.000Z [neutral] Risk: low
  On April 7, 2025, iBio, Inc. filed an 8-K report detailing a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing does not
• iBio Faces NYSE American Delisting Risk — 8-K · 2025-02-19T00:00:00.000Z [bearish] Risk: high
  On February 19, 2025, iBio, Inc. filed an 8-K to report its notice of delisting or failure to satisfy continued listing rules. The company is facing potential d
• iBio, Inc. Q2 2025: Assets $9.1M, Liabilities $1.9M — 10-Q · 2025-02-10T00:00:00.000Z [neutral] Risk: medium
  iBio, Inc. filed a 10-Q for the period ending December 31, 2024. The company reported total assets of $9.132 million and total liabilities of $1.856 million for
• iBio, Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: medium
  On January 10, 2025, iBio, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also repo
• iBio, Inc. Files 8-K Report — 8-K · 2025-01-10T00:00:00.000Z [neutral] Risk: low
  On January 10, 2025, iBio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financial statements a
• iBio, Inc. Files 8-K with Material Agreements and Equity Sales — 8-K · 2025-01-02T00:00:00.000Z [neutral] Risk: medium
  On December 31, 2024, iBio, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported on u
• iBio, Inc. Announces Stockholder Meeting for Reverse Stock Split — 8-K · 2024-11-25T00:00:00.000Z [neutral] Risk: medium
  On November 21, 2024, iBio, Inc. filed an 8-K report detailing its financial results and announcing a special meeting of stockholders. The meeting, scheduled fo
• SC 13G Filing — SC 13G · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• iBio, Inc. Files 8-K: Financials and Operations Update — 8-K · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  On November 12, 2024, iBio, Inc. filed an 8-K report detailing its financial results and condition. The company, formerly known as iBioPharma, Inc. and InB:Biot
• 8-K Filing — 8-K · 2024-10-23T00:00:00.000Z [neutral]
• iBio, Inc. Files Definitive Proxy Statement — DEF 14A · 2024-10-10T00:00:00.000Z [neutral] Risk: medium
  iBio, Inc. filed its definitive proxy statement on October 10, 2024, for its annual meeting. The filing details the company's governance, executive compensation
• iBio, Inc. Files 2024 10-K Amendment — 10-K/A · 2024-09-24T00:00:00.000Z [neutral] Risk: medium
  iBio, Inc. filed an amendment to its 2024 10-K on September 24, 2024, for the fiscal year ending June 30, 2024. The company, formerly known as iBioPharma, Inc.,
• iBio, Inc. Files 2024 10-K Report — 10-K · 2024-09-20T00:00:00.000Z [neutral] Risk: medium
  iBio, Inc. filed its 2024 10-K report for the fiscal year ending June 30, 2024. The company, formerly known as iBioPharma, Inc., is involved in the pharmaceutic
• iBio Appoints Thomas D'Alonzo CEO, Hikes Executive Compensation — 8-K · 2024-07-26T00:00:00.000Z [neutral] Risk: medium
  On July 23, 2024, iBio, Inc. announced the appointment of Thomas L. D'Alonzo as its new Chief Executive Officer and a member of the Board of Directors. D'Alonzo
• iBio Appoints Thomas D'Alonzo CEO, Sets Salary — 8-K · 2024-07-09T00:00:00.000Z [neutral] Risk: medium
  On July 2, 2024, iBio, Inc. announced the appointment of Thomas L. D'Alonzo as Chief Executive Officer and a member of the Board of Directors. D'Alonzo, previou
• iBio, Inc. Files 8-K: Material Definitive Agreement — 8-K · 2024-07-03T00:00:00.000Z [neutral] Risk: medium
  On July 3, 2024, iBio, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits, but speci
• iBio, Inc. Reports Key Corporate Events and Asset Changes — 8-K · 2024-06-05T00:00:00.000Z [neutral] Risk: medium
  On May 31, 2024, iBio, Inc. reported the termination of a material definitive agreement and the completion of an acquisition or disposition of assets. The compa
• 8-K Filing — 8-K · 2024-06-03T00:00:00.000Z [neutral]
• iBio, Inc. Secures $1.5M in Equity Financing — 8-K · 2024-05-20T00:00:00.000Z [neutral] Risk: medium
  On May 14, 2024, iBio, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with an accredited investor. This agreem
• iBio, Inc. Files 8-K for Operations and Financials — 8-K · 2024-05-13T00:00:00.000Z [neutral] Risk: low
  On May 13, 2024, iBio, Inc. filed an 8-K report to disclose information regarding its results of operations and financial condition, as well as financial statem
• SC 13G/A Filing — SC 13G/A · 2024-04-09T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-04-08T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-04-05T00:00:00.000Z [neutral]
• iBio Secures Up to $10M in Equity Financing — 8-K · 2024-04-01T00:00:00.000Z [neutral] Risk: medium
  On March 26, 2024, iBio, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with an accredited investor. This agre
• SC 13G Filing — SC 13G · 2024-04-01T00:00:00.000Z [neutral]
• iBio Reports Material Agreement & Asset Transaction — 8-K · 2024-02-26T00:00:00.000Z [neutral] Risk: medium
  iBio, Inc. filed an 8-K on February 26, 2024, reporting an event that occurred on February 25, 2024. The filing indicates an entry into a material definitive ag
• iBio, Inc. Changes Certifying Accountant — 8-K · 2024-02-21T00:00:00.000Z [neutral] Risk: low
  iBio, Inc. filed an 8-K on February 21, 2024, reporting a change in its certifying accountant. The earliest event reported was February 15, 2024. The filing ind
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• iBio, Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · 2024-02-09T00:00:00.000Z [neutral] Risk: medium
  iBio, Inc. (IBIO) filed a Quarterly Report (10-Q) with the SEC on February 9, 2024. iBio, Inc. filed a 10-Q report for the period ending December 31, 2023. The
• iBio Reports New Material Agreement & Financial Obligation — 8-K · 2024-01-19T00:00:00.000Z [neutral]
  iBio, Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 16, 2024, related to entering a material definitive agreement and creat
• iBio Changes Headquarters to Bryan, Texas — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  iBio, Inc. filed an 8-K on January 8, 2024, primarily to update its corporate address from 600 Madison Avenue, Suite 1601, New York, NY to 8800 HSC Parkway, Bry
• Sabby Volatility Fund Takes 9.99% Stake in iBio (IBIO) — SC 13G · 2024-01-04T00:00:00.000Z [bullish]
  Sabby Volatility Warrant Master Fund, Ltd., an investment fund based in the Cayman Islands, has reported a significant stake in iBio, Inc. (IBIO). As of Decembe